Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed.
PURPOSE: This clinical trial is studying the side effects of doxorubicin hydrochloride
liposome and to see how well it works in treating women with ductal carcinoma in situ
undergoing surgery.